How low an LDL-C should we go with statin therapy?

Current Atherosclerosis Reports

Volumn 16, Issue 2, 2014, Pages

  Kostis, William J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cardiovascular risk; Cost effectiveness; Guidelines; High sensitivity c reactive protein; hsCRP; LDL cholesterol; Primary prevention; Secondary prevention; Statins

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; AGE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; INFLAMMATION; MYALGIA; MYOPATHY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SMOKING; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; DRUG EFFECT; METABOLISM; PRACTICE GUIDELINE; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 84891527956     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0388-7     Document Type: Review

References (63)

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
2. •• Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-220. Details the increasing burden of atherosclerotic disease globally, the prevalence of risk factors (including hypercholesterolemia), and how improvements in cholesterol control have resulted in lower rates of cardiovascular events in the United States.
3. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serumcholesterol, blood pressure, andmortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-6.
4. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins AI and B, and HDL density subfractions the atherosclerosis risk in communities (ARIC) study. Circulation. Am Heart Assoc. 2001;104:1108-13.
5. Leeper NJ, Ardehali R, deGoma EM, Heidenreich PA. Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival. Circulation. 2007;116:613-8.
6. Sachdeva A, Cannon CP, Deedwania PC, Labresh KA, Smith SC, Dai D, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157:111-2.
7. • Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-6. Intensive lipid lowering with high doses of potent statins results in lower rates of cardiovascular events, and the greatest benefits are observed with the greatest reductions in LDL-cholesterol. There was no adverse effect on safety with lower achieved LDL levels.
8. LaRosa JC, Grundy SM, Kastelein JJP, Kostis JB, Greten H. Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100:747-52.
9. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol. 2006;17:626-30.
10. Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, et al. Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke. 2007;38:3198-204.
11. Lee KH, Jeong MH, Ahn Y, Cho MC, Kim CJ, Kim YJ. New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. J Korean Med Sci. 2013;28:173-80.
12. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35.
13. Collaborators CTTC. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
14. Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention ofmajor coronary events and all-causemortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20:641-57.
15. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1, CD004816.
16. • Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. In the JUPITER trial of persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events, despite the fact that nearly all study participants had baseline lipid levels that were well below the threshold for treatment according to current prevention guidelines. In this trial, myopathy, hepatic injury, and cancer did not occur more frequently with rosuvastatin than with placebo.
17. Heart Outcomes Prevention Evaluation-3 (HOPE-3) [Internet]. [cited 2013 Nov 3]. Available from: http://clinicaltrials.gov/ct2/show/NCT00468923
18. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, Dolor RJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1481-501.
19. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611-9.
20. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the national cholesterol education panel iii guidelines perform? J Am Coll Cardiol. 2003;41:1475-9.
21. • Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572-82. Statin therapy is associated with significant decreases in cardiovascular events and in all-cause mortality in women and men. Therefore, statin therapy should be used in appropriate patients without regard to sex.
22. Kostis WJ. Absolute risk reduction due to statin use according to sex. J Am Coll Cardiol. 2012;60:1580.
23. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, et al. Clinical Predictors of Plaque Progression Despite Very Low Levels of Low-Density Lipoprotein Cholesterol. J Am Coll Cardiol Elsevier Inc. 2010;55:2736-42.
24. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72:2365-73.
25. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-6.
26. Mitchell AP, Simpson RJ. Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. BMC Res Notes. 2012;5:373.
27. • Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150:243-54. The ATP III guidelines are relatively cost-effective and would have a large public health impact if implemented fully in the United States.
28. Authors/Task Force Members, Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2012;33:1635-701.
29. The Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet Elsevier Ltd. 2010;375:132-40.
30. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20-8.
31. The Emerging Risk Factors Collaboration. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. N Engl J Med. 2012;367:1310-20.
32. Heart Protection Study Collaborative Group, Jonathan E, Derrick B, Emma L, Sarah P, John D, et al. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377:469-76.
33. Sever PS, Poulter NR, Chang CL, Thom SAM, Hughes AD, Welsh P, et al. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the anglo-scandinavian cardiac outcomes trial lipid-lowering arm. J Am Coll Cardiol. 2013;62:717-29.
34. • C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548-8. Human genetic data indicate that C reactive protein concentration itself is unlikely to be a causal factor in coronary heart disease. However, there is considerable evidence that persistent inflammation might contribute to coronary heart disease.
35. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25:13-3.
36. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004. pp. 227-39.
37. Everett B, Mora S, Grossbard J, MacFadyen J, Ridker P. Safety Profile of Statin-Treated Patients with LDL-C < 30 mg/dL. J Am Coll Cardiol Am Coll Cardiol Found. 2012;59:E1619.
38. Kanat M, Sipahioglu M, Arinc H, Serin E, Yildiz O, Tunckale A, et al. Is lipid lowering treatment aiming for very low LDL levels safe in terms of the synthesis of steroid hormones? Med Hypotheses. 2007;69:104-12.
39. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788-97.
40. Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcome. 2013;6:390-9.
41. Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G, et al. SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013.
42. Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. Am Heart J Mosby Inc. 2013;165:1008-14.
43. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circ Cardiovasc Genet. 2012;5:257-64.
44. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol Eur Assoc Study Liver. 2012;56:374-80.
45. Cohen DE, Anania FA, Chalasani N. An Assessment of Statin Safety by Hepatologists. Am J Cardiol. 2006;97:S77-81.
46. • Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-71. In the JUPITER primary prevention trial, participants allocated to rosuvastatin treatment had a 28% increased likelihood of diabetes diagnosis if they had risk factors for diabetes, and no increased risk otherwise. The cardiovascular and mortality benefits of statin therapy exceeded the diabetes hazard, including in participants at high risk of developing diabetes.
47. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924-9.
48. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet Elsevier. 2010;375:735-42.
49. Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556-64.
50. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74-80.
51. Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60:875-81.
52. • Collaborators CTTC. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet Elsevier Ltd. 2012;380:581-90. Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularization, and stroke by about one fifth per mmol/L (38.7 mg/dl) reduction in LDL cholesterol, irrespective of the initial lipid profile or other presenting characteristics.
53. Heart Protection Study Collaborative Group. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med. 2005;3:6.
54. Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23:1099-111.
55. Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TL. Statins and prostate cancer prevention: where we are now, and future directions. Nat Clin Pract Urol. 2008;5:376-87.
56. Matsushita Y, Sugihara M, Kaburagi J, Ozawa M, Iwashita M, Yoshida S, et al. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. Pharmacoepidemiol Drug Saf. 2010;19:196-202.
57. Goldstein LB, Amarenco P, Szarek M, Callahan A, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70:2364-70.
58. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43:2149-56.
59. Lee J-G, Koh SJ, Yoo SY, Yu JR, Lee SA, Koh G, et al. Characteristics of subjects with very low serum low-density lipoprotein cholesterol and the risk for intracerebral hemorrhage. Korean J Intern Med. 2012;27:317-26.
60. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50:S172-7.
61. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. PCSK9 R46L, Low-Density LipoproteinCholesterol Levels, and Risk of Ischemic Heart Disease. J Am Coll Cardiol Elsevier Inc. 2010;55:2833-42.
62. •• Brown MS, Goldstein JL. Lowering LDL - Not Only How Low, But How Long? Science. 2006;311:1721-3. The much greater reduction in coronary heart disease incidence among individuals with a PCSK9 mutation, as compared with those treated with statin therapy achieving the same LDL-C reduction, suggests that the duration of LDL-C lowering should also be emphasized. A public health program aimed at lowering LDL-C levels before the atherosclerotic process has become advanced is proposed.
63. Kostis WJ, Kostis JB. Age-neutral guidelines for the primary prevention of cardiovascular disease. J Clin Hypertens (Greenwich). 2009;11:644-5.